Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: Current aspects and new perspectives

Frontiers in Endocrinology

Volumn 5, Issue FEB, 2014, Pages

  Baldelli, Roberto ^a   Barnabei, A ^a   Rizza, L ^b   Isidori, A M ^b   Rota, F ^a   Di Giacinto, P ^c   Paoloni, A ^a   Torino, F ^c   Corsello, S M ^d   Lenzi, A ^b   Appetecchia, M ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Carcinoid; Lanreotide; Neuroendocrine tumors; Octreotide; Somatostatin analogs

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; CHROMOGRANIN A; FIBROBLAST GROWTH FACTOR; LUTETIUM 177; OCTREOTIDE; SEROTONIN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; TACHYKININ; VASCULOTROPIN; YTTRIUM 90;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CARCINOID; COMPUTER ASSISTED TOMOGRAPHY; ELECTROLYTE DISTURBANCE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MULTICENTER STUDY (TOPIC); NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMATOSTATINOMA; TUMOR GROWTH; TUMOR VOLUME;

EID: 84901041783     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00007     Document Type: Review

References (107)

1. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut (2005) 54(Suppl 4):iv1-16. doi: 10.1136/gut.2004.053314.
2. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 9(1):61-72. doi:10.1016/S1470-2045(07)70410-2.
3. Pearse AG. The cytochemistry and ultrastructure of polypeptide hormoneproducing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem (1969) 17:303-13. doi:10.1177/17.5.303.
4. Solcia E, Kloppel G, Sobin LH. Histological Typing of Endocrine Tumours. World Health Organization International Histological Classification of Tumours, Second Edition. Heidelberg: Springer (2000).
5. Pape UF, Jann H, Muller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer (2008) 113(2):256-65. doi:10.1002/cncr.23549.
6. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology (2004) 80(6):394-424. doi:10.1159/000085237.
7. Beneyto M, Morris HM, Rovensky KC, Lewis DA. Lamina-and cell-specific alterations in cortical somatostatin receptor 2 mRNA expression in schizophrenia. Neuropharmacology (2012) 62(3):1598-605. doi:10.1016/j.neuropharm.2010.12.029.
8. Pasquali D, Notaro A, Bonavolonta' G, Vassallo P, Bellastella A, Sinisi AA. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease. J Clin Endocrinol Metab (2002) 87(11):5125-9. doi:10.1210/jc.2002-020790.
9. Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol (1992) 43(1-3):27-35. doi:10.1016/0960-0760(92)90184-K.
10. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res (1996) 56(8):1823-7.
11. Ferone D, Gatto F, Arvigo M, Resmini E, Boschetti M, Teti C, et al. The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol (2009) 42(5):361-70. doi:10.1677/JME-08-0162.
12. Papotti M, Bongiovanni M, Volante M, Allia E, LandolfiS, Helboe L, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch (2002) 440:461-75. doi:10.1007/s00428-002-0609-x.
13. Janson ET, Oberg K. Neuroendocrine tumors-somatostatin receptor expression and somatostatin analog treatment. Cancer Chemother Biol Response Modif (2003) 21:535-46. doi:10.1016/S0921-4410(03)21025-5.
14. Oberg K. Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology (2004) 80:57-61. doi:10.1159/000080743.
15. Oberg K, Kvols L, Caplin M. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol (2004) 15(6):966-73. doi:10.1093/annonc/mdh216.
16. Antonijoan RM, Barbanoj MJ, Cordero JA, Peraire C, Obach R, Valles J, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol (2004) 56(4):471-6. doi:10.1211/0022357023123.
17. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol (2002) 146(5):707-16. doi:10.1530/eje.0.1460707.
18. Pasquali D, Rossi V, Conzo G, Pannone G, Bufo P, De Bellis A, et al. Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. J Mol Endocrinol (2008) 40(6):263-71. doi:10.1677/JME-08-0012.
19. Plockinger U. Biotherapy. Best Pract Res Clin Endocrinol Metab (2007) 21:145-62. doi:10.1016/j.beem.2007.01.002.
20. Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer (2008) 15(3):701-20. doi:10.1677/ERC-07-0288.
21. de Herder WW, Kwekkeboom DJ, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ, et al. Somatostatin receptor imaging for neuroendocrine tumors. Pituitary (2006) 9(3):243-8. doi:10.1007/s11102-006-0270-5.
22. Janson ET, Kalkner KM, Eriksson B, Westlin JE, Oberg K. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors. Nucl Med Biol (1999) 26(8):877-82. doi:10.1016/S0969-8051(99)00059-1.
23. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol (1999) 10(Suppl 2):S23-9. doi:10.1023/A:1027396313397.
24. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog (177Lu-DOTA0, Tyr3)octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol (2005) 23(12):2754-62. doi:10.1200/JCO.2005.08.066.
25. Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs. Metabolism (1990) 39(9 Suppl 2):152-5. doi:10.1016/0026-0495(90)90235-5.
26. Lamberts SW, de Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab (2002) 13:451-7. doi:10.1016/S1043-2760(02)00667-7.
27. van Eyck CH, Bruining HA, Reubi JC, Bakker WH, Oei HY, Krenning EP, et al. Use of isotope-labeled somatostatin analogs for visualization of islet cell tumors. World J Surg (1993) 17(4):444-7. doi:10.1007/BF01655102.
28. Dogliotti L, Tampellini M, Stivanello M, Gorzegno G, Fabiani L. The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy. Ann Oncol (2001) 12:S105-9. doi:10.1023/A:1012465215904.
29. Bombardieri E, Seregni E, Savelli G, Villano C, Castellani MR, Cirillo F, et al. Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors. J Endocrinol Invest (2003) 26(Suppl 8):63-69.
30. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol (1987) 5:1502-22.
31. di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer (1996) 77(2):402-8. doi:10.1002/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4.
32. Delaunoit T, Neczyporenko F, Rubin J, Erlichman C, Hobday TJ. Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol (2008) 103(2):475-83. doi:10.1111/j.1572-0241.2007.01643.x.
33. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci (1982) 31(11):1133-40. doi:10.1016/0024-3205(82)90087-X.
34. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol (1999) 17(2):600-6.
35. O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouche O, Catus F, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer (2000) 88(4):770-6. doi:10.1002/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0.
36. Ruszniewski P, Ish-Shalom S, Wymenga M, O'Toole D, Arnold R, Tomassetti P, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged release formulation of lanreotide. Neuroendocrinology (2004) 80(4):244-51. doi:10.1159/000082875.
37. Kvols LK, Oberg KE, O'Dorisio TM, Mohideen P, de Herder WW, Arnold R, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer (2012) 19(5):657-66. doi:10.1530/ERC-11-0367.
38. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med (1999) 340:858-68. doi:10.1056/NEJM199903183401107.
39. Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology (2004) 80:51-6. doi:10.1159/000080742.
40. Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol (2005) 152:757-67. doi:10.1530/eje.1.01901.
41. Hearn PR, Ahmed M, Woodhouse NJ. The use of SMS 201-995 (somatostatin analogue) in insulinomas. Additional case report and literature review. Horm Res (1998) 29:211-3.
42. Hearn PR, Reynolds CL, Johansen K, Woodhouse NJ. Lung carcinoid with Cushing's syndrome: control of serum ACTH and cortisol levels using SMS 201-995 (sandostatin). Clin Endocrinol (Oxf) (1988) 28:181-5.
43. Tanaka Y, Funahashi H, Imai T, Naruse T, Suzumura K, Oda Y. The effectiveness of administering a minimal dose of octreotide long-term prior to surgery for insulinoma: report of a case. Surg Today (2000) 30:541-3. doi:10.1007/s005950070124.
44. Verschoor L, Uitterlinden P, Lamberts SW, Del Pozo E. On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma. Clin Endocrinol (Oxf) (1986) 25:555-60. doi:10.1111/j.1365-2265.1986.tb03609.x.
45. von Eyben FE, Grodum E, Gjessing HJ, Hagen C, Nielsen H. Metabolic remission with octreotide in patients with insulinoma. J Intern Med (1994) 235:245-8. doi:10.1111/j.1365-2796.1994.tb01067.x.
46. Casadei R, Tomassetti P, Rossi C, la Donna M, Migliori M, Marrano D. Treatment of metastatic glucagonoma to the liver: case report and literature review. Ital J Gastroenterol Hepatol (1999) 31:308-12.
47. Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther (2000) 14:557-60. doi:10.1046/j.1365-2036.2000.00738.x.
48. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore) (1996) 75:53-63. doi:10.1097/00005792-199603000-00002.
49. Grozinsky-Glasberg S, Grossman AB, Korbonits M. The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol (2008) 286:238-50. doi:10.1016/j.mce.2007.10.006.
50. Appetecchia M, Ferretti E, Carducci M, Izzo F, Carpanese L, Marandino F, et al. Malignant glucagonoma. New options of treatment. J Exp Clin Cancer Res (2006) 25(1):135-9.
51. Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res (1999) 18:13-22.
52. Angeletti S, Corleto VD, Schillaci O, Marignani M, Annibale B, Moretti A, et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut (1998) 42:792-4. doi:10.1136/gut.42.6.792.
53. Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ. Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg (2007) 12:382-93. doi:10.1007/s11605-007-0177-0.
54. Song S, Shi R, Li B, Liu Y. Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors. Pancreas (2009) 38(7):811-4. doi:10.1097/MPA.0b013e3181b2bc7c.
55. Nakayama S, Yokote T, Kobayashi K, Hirata Y, Hiraiwa T, Komoto I, et al. VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome. Endocrine (2009) 35:143-6. doi:10.1007/s12020-009-9146-6.
56. Schally AV. Oncological applications of somatostatin analogues. Cancer Res (1988) 48:6977-85.
57. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med (1998) 217:143-52. doi:10.3181/00379727-217-44216.
58. Weckbecker G, Raulf F, Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther (1993) 60:245-64.
59. Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers (2002) 66:161-83. doi:10.1002/bip.10256.
60. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab (2004) 15:300-10. doi:10.1016/j.tem.2004.07.002.
61. Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Antitumor effects of somatostatin. Mol Cell Endocrinol (2008) 286:230-7. doi:10.1016/j.mce.2008.02.002.
62. Jensen RT. Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol (2000) 12:368-77. doi:10.1097/00001622-200007000-00015.
63. Reubi JC. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. Acta Endocrinol (Copenh) (1985) 109:108-14.
64. Sinisi AA, Bellastella A, Prezioso D, Nicchio MR, Lotti T, Salvatore M, et al. Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer. J Clin Endocrinol Metab (1997) 82(8):2566-9. doi:10.1210/jc.82.8.2566.
65. Scarpignato C, Pelosini I. Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy (2001) 47:1-29. doi:10.1159/000049157.
66. Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol (1997) 36:607-14. doi:10.3109/02841869709001323.
67. Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol (1997) 8:1041-4. doi:10.1023/A:1008205415035.
68. Faiss S, Rath U, Mansmann U, Caird D, Clemens N, Riecken EO, et al. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion (1999) 60:469-76. doi:10.1159/000007693.
69. Lawnicka H, Stepien H, Wyczolkowska J, Kolago B, Kunert-Radek J, Komorowski J. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun (2000) 268:567-71. doi:10.1006/bbrc.2000.2119.
70. Treiber G, Wex T, Rocken C, Fostitsch P, Malfertheiner P. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol (2006) 132:699-708. doi:10.1007/s00432-006-0118-4.
71. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, et al. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol (2007) 13:3164-70.
72. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev (1991) 12:450-82. doi:10.1210/edrv-12-4-450.
73. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy (2001) 47:30-9. doi:10.1159/000049159.
74. Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, et al. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res (1997) 3:265-72.
75. Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, et al. Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs (1997) 15:77-86. doi:10.1023/A:1005774713202.
76. Anthony L, Johnson D, Hande K, ShaffM, Winn S, Krozely M, et al. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol (1993) 32:217-23. doi:10.3109/02841869309083915.
77. Kvols LK, Woltering EA. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs (2006) 17:601-8. doi:10.1097/01.cad.0000210335.95828.ed.
78. Arnold R, Benning R, Neuhaus C, Rolwage M, Trautmann ME. Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion (1993) 54:72-5. doi:10.1159/000201081.
79. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut (1996) 38:430-8. doi:10.1136/gut.38.3.430.
80. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer (1993) 72:244-8. doi:10.1002/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q.
81. Panzuto F, Di Fonzo M, Iannicelli E, Sciuto R, Maini CL, Capurso G, et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol (2006) 17:461-6. doi:10.1093/annonc/mdj113.
82. Faiss S, Scherubl H, Riecken EO, Wiedenmann B. Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Recent Results Cancer Res (1996) 142:193-207. doi:10.1007/978-3-642-80035-1_12.
83. Welin SV, Janson ET, Sundin A, Stridsberg M, Lavenius E, Granberg D, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol (2004) 151:107-12. doi:10.1530/eje.0.1510107.
84. Arnold R, Rinke A, Klose KJ, Muller HH, Wied M, Zamzow K, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol (2005) 3:761-71. doi:10.1016/S1542-3565(05)00481-7.
85. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol (2009) 27:4656-63. doi:10.1200/JCO.2009.22.8510.
86. Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer (2002) 94:331-43. doi:10.1002/cncr.10195.
87. Prommegger R, Bale R, Ensinger C, Sauper T, Profanter C, Knoflach M, et al. Gastric carcinoid type I tumour: new diagnostic and therapeutic method. Eur J Gastroenterol Hepatol (2003) 15:705-7. doi:10.1097/00042737-200306000-00020.
88. Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL. Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol (2004) 39:621-8. doi:10.1080/00365520410005225.
89. Dworakowska D, Wlodek E, Leontiou C, Igreja S, Cakir M, Teng M, et al. Activation of Raf/MEK/ERK and PI3K/Akt/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer (2009) 16(4):1329-38. doi:10.1677/ERC-09-0101.
90. Romeo S, Milione M, Gatti A, Fallarino M, Corleto V, Morano S, et al. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2. Horm Res (2006) 65:120-5. doi:10.1159/000091408.
91. Bondanelli M, Ambrosio MR, Zatelli MC, Cavazzini L, Al Jandali Rifa'y L, Degli Uberti EC. Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy. World J Gastroenterol (2005) 11:2041-4.
92. Klijn JG, HoffAM, Planting AS, Verweij J, Kok T, Lamberts SW, et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer (1990) 62:627-30. doi:10.1038/bjc.1990.343.
93. Renzullo A, Accardo G, Esposito D, De Bellis A, Bizzarro A, Romano M, et al. Hashimoto's thyroiditis and ECL hyperplasia: early detection and SST analog treatment. Eur J Inflamm (2013). (in press).
94. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol (2000) 95:3276-81. doi:10.1111/j.1572-0241.2000.03210.x.
95. Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer (2001) 37:1014-9. doi:10.1016/S0959-8049(01)00073-9.
96. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging (2003) 30:781-93. doi:10.1007/s00259-003-1184-3.
97. O'Toole D, Saveanu A, Couvelard A, Gunz G, Enjalbert A, Jaquet P, et al. The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol (2006) 155:849-57. doi:10.1530/eje.1.02307.
98. Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med (2000) 343:551-4. doi:10.1056/NEJM200008243430805.
99. Ferolla P, Faggiano A, Grimaldi F, Ferone D, Scarpelli G, Ramundo V, et al. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J Endocrinol Invest (2012) 35(3):326-31. doi:10.3275/7869.
100. Fjälling M, Andersson P, Forssell-Aronsson E, Grétarsdóttir J, Johansson V, Tisell LE, et al. Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. J Nucl Med (1996) 37:1519-21.
101. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem (2000) 7:971-94. doi:10.2174/0929867003374516.
102. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab (2007) 21:111-29. doi:10.1016/j.beem.2007.01.007.
103. de Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med (2002) 32(2):133-40. doi:10.1053/snuc.2002.31027.
104. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu-and 90Y-labeled somatostatin analogs. J Nucl Med (2005) 46(Suppl 1):13S-7S.
105. Oberg K, Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab (2005) 19:265-76. doi:10.1016/j.beem.2004.11.016.
106. Chan JA, Kulke MK. Emerging therapies for the treatment of patients with advanced neuroendocrine tumors. Expert Opin Emerg Drugs (2007) 12:253-70. doi:10.1517/14728214.12.2.253.
107. Tiensuu Janson EM, Ahlström H, Andersson T, Oberg KE. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer (1992) 28:1647-50. doi:10.1016/0959-8049(92)90060-F.